Factors accelerating liver fibrosis progression in renal transplant patients receiving ribavirin monotherapy for chronic hepatitis C

Journal of Medical Virology

Volumn 76, Issue 1, 2005, Pages 61-68

  Kamar, Nassim ^a,b   Boulestin, Anne ^b   Selves, Janick ^b   Esposito, Laure ^a   Sandres Saune, Karine ^b   Stébenet, Michèle ^b   Chatelut, Etienne ^c   Durand, Dominique ^a   Rostaing, Lionel ^a   Izopet, Jacques ^b  

^a CHU RANGUEIL   (France)

^b CHU PURPAN   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Fibrosis; Hepatitis C virus; Hepatosiderosis; Renal transplant patients; Ribavirin

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; GAMMA INTERFERON; INTERLEUKIN 10; MESSENGER RNA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RIBAVIRIN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; HEMOLYSIS; HEPATITIS C; HUMAN; IRON BALANCE; IRON OVERLOAD; KIDNEY TRANSPLANTATION; LIVER BIOPSY; LIVER FIBROSIS; MALE; NONHUMAN; PRESSURE MEASUREMENT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ANEMIA, HEMOLYTIC; ANTIVIRAL AGENTS; CYTOKINES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IRON; IRON OVERLOAD; KIDNEY TRANSPLANTATION; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RIBAVIRIN; TRANSFERRIN;

HEPATITIS C VIRUS;

EID: 20144388309     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20323     Document Type: Article

References (30)

1. Alric L, Plaisier E, Thebault S, Peron JM, Rostaing L, Pourrat J, Ronco P, Piette JC, Cacoub P. 2004. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis 43:617-623.
2. Angelucci E, Muretto P, Nicolucci A, Baronciani D, Erer B, Gaziev J, Ripalti M, Sodani P, Tomassoni S, Visani G, Lucarelli G. 2002. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 100:17-21.
3. Bedossa P, Poynard T. 1996. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24:289-293.
4. Bruchfeld A, Stahle L, Andersson J, Schvarcz R. 2001. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection - A pilot study. J Viral Hepat 8:287-292.
5. Bruchfeld A, Lindahl K, Schvarcz R, Stahle L. 2002. Dosage of ribavirin in patients with hepatitis C should be based on renal function: A population pharmacokinetic analysis. Ther Drug Monit 24:701-708.
6. Bruchfeld A, Lindahl K, Stahle L, Soderberg M, Schvarcz R. 2003. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 18:1573-1580.
7. Cattral MS, Hemming AW, Wanless IR, Al Ashgar H, Krajden M, Lilly L, Greig PD, Levy GA. 1999. Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation. Transplantation 67:1277-1280.
8. Conrad M, Umbreit J. 2000. Iron absorption and transport-An update. Am J Hematol 64:287-298.
9. Di Bisceglie AM, Bacon BR, Kleiner DE, Hoofnagle JH. 1994. Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. J Hepatol 21:1109-1112.
10. Diwakaran HH, Befeler AS, Britton RS, Brunt EM, Bacon BR. 2002. Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection. J Hepatol 36: 687-691.
11. Fang SH, Hwang LH, Chen DS, Chiang BL. 2000. Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level. J Hepatol 33: 791-798.
12. Fehr T, Riehl HM, Nigg L, Grüte E, Ammann P, Renner EL, Ambühl PM. 2003. Evaluation of hepatitis B and hepatitis C virus-infected renal allograft recipients with liver biopsy and noninvasive parameters. Am J Kidney Dis 42:193-201.
13. Fiel MI, Schiano TD, Guido M, Thung SN, Lindsay KL, Davis GL, Lewis JH, Seeff LB, Bodenheimer HC Jr. 2000. Increased hepatic iron deposition resulting from treatment of chronic hepatitis C with ribavirin. Am J Clin Pathol 113:35-39.
14. Gane EJ, Tibbs CJ, Ramage JK, Portmann BC, Williams R. 1995. Ribavirin therapy for hepatitis C infection following liver transplantation. Transpl Int 8:61-64.
15. Heagy W, Crumpacker C, Lopez PA, Finberg RW. 1991. Inhibition of immune functions by antiviral drugs. J Clin Invest 87:1916-1924.
16. Hultgren C, Milich DR, Weiland O, Sallberg M. 1998. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 79:2381-2391.
17. Izopet J, Rostaing L, Sandres K, Cisterne JM, Pasquier C, Rumeau JL, Duffaut M, Durand D, Puel J. 2000. Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. J Infect Dis 181:852-858.
18. Kamar N, Sandres-Saune K, Selves J, Ribes D, Cointault O, Durand D, Izopet J, Rostaing L. 2003. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: Effects on renal function and liver histology. Am J Kidney Dis 42:184-192.
19. Kamar N, Chatelut E, Manolis E, Lafont T, Izopet J, Rostaing L. 2004. Ribavirin pharmacokinetics in renal and liver transplant patients: Evidence that it depends on renal function. Am J Kidney Dis 43: 140-146.
20. Kamar N, Rostaing L, Selves J, Sandres-Sauné K, Alric L, Durand D, Izopet J. XXXX. Natural history of hepatitis C virus-related liver fibrosis after renal transplantation. Am J Transplant (in press).
21. Lin CC, Philips L, Xu C, Yeh LT. 2004. Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers. J Clin Pharmacol 44:265-275.
22. Lindahl K, Schvarcz R, Bruchfeld A, Stahle L. 2004. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepat 11:84-87.
23. Ning Q, Brown D, Parodo J, Cattral M, Gorczynski R, Cole E, Fung L, Ding JW, Liu MF, Rotstein O, Phillips MJ, Levy G. 1998. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fg12 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 160: 3487-3493.
24. Quadri R, Giostra E, Roskams T, Pawlotsky JM, Mentha G, Rubbia-Brandt L, Perrin L, Hadengue A, Negro F. 2002. Immunological and virological effects of ribavirin in hepatitis C after liver transplantation. Transplantation 73:373-378.
25. Saab S, Hu R, Ibrahim AB, Goldstein LI, Kunder G, Durazo F, Han S, Yersiz H, Ghobrial RM, Farmer DG, Busuttil RW, Lassman C. 2003. Discordance between ALT values and fibrosis in liver transplant recipients treated with ribavirin for recurrent hepatitis C. Am J Transplant 3:328-333.
26. Sabry AA, Sobh MA, Sheaashaa HA, Kudesia G, Wild G, Fox S, Wagner BE, Irving WL, Grabowska A, El-Nahas AM. 2002. Effect of combination therapy (ribavirin and interferon) in HCV-related glomerulopathy. Nephrol Dial Transplant 17:1924-1930.
27. Searle J, Kerr JF, Halliday JW, Powel LW. 1994. Iron storage disease. In: Mac Sween RNM, Anthony P, Scheuer PJ, Burt AD, Portmann BC, editors. Pathology of the Liver. Edinburgh: Churchill Livingstone. pp 214-241.
28. Tan CITL, Brouwer JT, Glue P, van Leusen R, Kauffmann RH, Schalm SW, de Vries RA, Vroom B. 2001. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: Results of a pilot study. Nephrol Dial Transplant 16:193.
29. Thompson JD, Higgins DG, Gibson TJ. 1994. CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucl Acids Res 22:4673-4680.
30. Zylberberg H, Nalpas B, Carnot F, Skhiri H, Fontaine H, Legendre C, Kreis H, Brechet C, Pol S. 2002. Severe evolution of chronic hepatitis C in renal transplantation: A case control study. Nephrol Dial Transplant 17:129-133.